ALERS Stock Overview
Engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Eurobio Scientific Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.35 |
| 52 Week High | €26.00 |
| 52 Week Low | €13.80 |
| Beta | -0.27 |
| 1 Month Change | 0.20% |
| 3 Month Change | -1.74% |
| 1 Year Change | 58.44% |
| 3 Year Change | 21.29% |
| 5 Year Change | 407.00% |
| Change since IPO | -74.55% |
Recent News & Updates
Recent updates
Eurobio Scientific Société anonyme (EPA:ALERS) Held Back By Insufficient Growth Even After Shares Climb 32%
Jul 31
Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Jul 29Estimating The Fair Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Apr 07Is Now The Time To Put Eurobio Scientific Société anonyme (EPA:ALERS) On Your Watchlist?
Mar 08Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Jan 03Improved Earnings Required Before Eurobio Scientific Société anonyme (EPA:ALERS) Stock's 28% Jump Looks Justified
Dec 13Should You Be Adding Eurobio Scientific Société anonyme (EPA:ALERS) To Your Watchlist Today?
Nov 20Eurobio Scientific Société anonyme's (EPA:ALERS) Earnings Are Of Questionable Quality
May 12Shareholder Returns
| ALERS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0.2% | -3.0% | 4.1% |
| 1Y | 58.4% | -27.9% | 3.7% |
Return vs Industry: ALERS exceeded the French Biotechs industry which returned -27.1% over the past year.
Return vs Market: ALERS exceeded the French Market which returned 4.3% over the past year.
Price Volatility
| ALERS volatility | |
|---|---|
| ALERS Average Weekly Movement | 2.7% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: ALERS has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALERS's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 329 | Denis Fortier | www.eurobio-scientific.com |
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, a molecular test for the surveillance of heart-transplant patients; cell culture media, molecular biology reagents, and proprietary antibodies; TQS (Tetanus Quick Stick) for the evaluation of patients’ immune status against tetanus; and EBX molecular biology family, which includes a range of tests for identifying various pathogens responsible for infectious diseases and assessing the magnitude of the infection. The company also develops other diagnostic products using molecular biology.
Eurobio Scientific Société anonyme Fundamentals Summary
| ALERS fundamental statistics | |
|---|---|
| Market cap | €254.61m |
| Earnings (TTM) | €6.64m |
| Revenue (TTM) | €144.73m |
38.3x
P/E Ratio1.8x
P/S RatioIs ALERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALERS income statement (TTM) | |
|---|---|
| Revenue | €144.73m |
| Cost of Revenue | €77.90m |
| Gross Profit | €66.83m |
| Other Expenses | €60.19m |
| Earnings | €6.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 46.18% |
| Net Profit Margin | 4.59% |
| Debt/Equity Ratio | 49.3% |
How did ALERS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 11:26 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eurobio Scientific Société anonyme is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wang Chong | Edison Investment Research |
| Stephanie Lefebvre | Gilbert Dupont |
| Damien Choplain | Gilbert Dupont |